Archive · 24 Jul 2026
FDA recalls cetirizine tablets over ranitidine contamination risk
The FDA has recalled some allergy medicine tablets because they might be mixed with another medicine called ranitidine.
This could cause serious allergic reactions in some people.
The tablets have red dots and different colors, which is not normal.
The company that made the medicine and the company that sells it are working with the FDA to get the bad medicine back.
If you have these tablets, you should check the numbers on the bottle and talk to a doctor before using them.
FDA recalls cetirizine tablets due to potential contamination with ranitidine.
Recall initiated by Unique Pharmaceutical Laboratories and Rising Pharma Holdings Inc.
Affected tablets have red dots and discoloration.
Contamination could cause severe allergic reactions, including anaphylaxis.
Consumers advised to check lot numbers and consult healthcare professionals.
- Who
- Unique Pharmaceutical Laboratories and Rising Pharma Holdings Inc.
- What
- Recall of cetirizine tablets due to potential ranitidine contamination.
- When
- Recall initiated on 18 July 2023.
- Where
- United States.
- Why
- Potential cross-contamination with ranitidine, which could cause severe allergic reactions.
Consumer Safety Advocates
Pharmaceutical Manufacturers
Recall Necessity
Consumer Safety Advocates
The recall is crucial to prevent potential severe allergic reactions due to contamination.
Pharmaceutical Manufacturers
The recall is a precautionary measure, and the risk to consumers is minimal.
- Product Name
- Cetirizine Hydrochloride Tablets USP 5 mg
- Manufacturer
- Unique Pharmaceutical Laboratories
- Distributor
- Rising Pharma Holdings Inc.
- Recall Date
- 18 July 2023
- Expiry Date
- October 2028
- National Drug Code (NDC)
- 16571-401-10
- Affected Lot Numbers
- GY825029, GY825030, GY825031, GY825032